CMBA
OXFD

C.M. Bidwell & Associates’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

C.M. Bidwell & Associates’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,290
Closed -$21K – 474
2020
Q1 		$21K Sell
2,290
-325
-12% -$4.54K 0.02% 238
2019
Q4 		$43K Buy
2,615
+15
+0.6% +$243 0.04% 256
2019
Q3 		$43K Sell
2,600
-4,150
-61% -$57.4K 0.04% 259
2019
Q2 		$93K Buy
+6,750
New +$103K 0.09% 181

Other funds holding OXFD

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

C.M. Bidwell & Associates's OXFD Position: Q2 2020 in Review

C.M. Bidwell & Associates sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2020, closing a stake of 2,290 shares — an estimated $21K sold.

C.M. Bidwell & Associates first reported a position in OXFD in Q2 2019 and held it in 4 quarters. The position peaked at $93K in Q2 2019. 65 funds tracked by Wall St. Rank hold OXFD as of Q2 2020.

  • C.M. Bidwell & Associates reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2020 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 2,290 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2020, an estimated $21K.
  • C.M. Bidwell & Associates first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q2 2019 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Oxford Immunotec Global PLC Ordinary Shares position peaked at $93K in Q2 2019.
  • 65 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2020.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2020, filed 14 Aug 2020.